Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
about
PharmGKB summary: very important pharmacogene information for N-acetyltransferase 2Membrane transporters in drug developmentXenobiotic, bile acid, and cholesterol transporters: function and regulation.Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes.Repositioning of Tyrosine Kinase Inhibitors as Antagonists of ATP-Binding Cassette Transporters in Anticancer Drug ResistanceRole of the breast cancer resistance protein (BCRP/ABCG2) in drug transport--an update.Membrane topology of the human breast cancer resistance protein (BCRP/ABCG2) determined by epitope insertion and immunofluorescence.Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP.Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice.Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain BarrierPharmacogenomic importance of ABCG2.Effect of pregnancy on nitrofurantoin disposition in mice.Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs.Identification of Febuxostat as a New Strong ABCG2 Inhibitor: Potential Applications and Risks in Clinical Situations.Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer.Drug transport by breast cancer resistance protein.Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.Impact of drug transporter pharmacogenomics on pharmacokinetic and pharmacodynamic variability - considerations for drug development.Effect of the ATP-binding cassette transporter ABCG2 on pharmacokinetics: experimental findings and clinical implications.Structure and function of BCRP, a broad specificity transporter of xenobiotics and endobiotics.Intestinal and hepatic drug transporters: pharmacokinetic, pathophysiological, and pharmacogenetic roles.Pharmacogenetics and population pharmacokinetics: impact of the design on three tests using the SAEM algorithm.Renal Drug Transporters and Drug Interactions.Acyclovir is a substrate for the human breast cancer resistance protein (BCRP/ABCG2): implications for renal tubular transport and acyclovir-induced nephrotoxicity.Transmembrane Domain Single-Nucleotide Polymorphisms Impair Expression and Transport Activity of ABC Transporter ABCG2.Circulating intestine-derived exosomal miR-328 in plasma, a possible biomarker for estimating BCRP function in the human intestines.Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer.Role of ABC transporters in cancer chemotherapy.Sulfasalazine disposition in a subject with 376C>T (nonsense mutation) and 421C>A variants in the ABCG2 gene.Different effects of the ABCG2 c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin.Quantitative population pharmacokinetic analysis of pravastatin using an enterohepatic circulation model combined with pharmacogenomic Information on SLCO1B1 and ABCC2 polymorphisms.Evaluation of Proposed In Vivo Probe Substrates and Inhibitors for Phenotyping Transporter Activity in Humans.Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting.ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin.PharmGKB summary: very important pharmacogene information for ABCG2.Preclinical absorption, distribution, metabolism, excretion and pharmacokinetics of a novel selective inhibitor of breast cancer resistance protein (BCRP).Dose-escalation study for the targeting of CD44v+ cancer stem cells by sulfasalazine in patients with advanced gastric cancer (EPOC1205).Evaluation of the usefulness of breast cancer resistance protein (BCRP) knockout mice and BCRP inhibitor-treated monkeys to estimate the clinical impact of BCRP modulation on the pharmacokinetics of BCRP substrates.Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model.Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.
P2860
Q27011622-7EF2C32E-3691-4498-86E9-3BD8AA918FC9Q29616802-FAC87A30-C4BA-44D8-BDC2-C711D38CCBB0Q33714593-91692837-6983-445C-B71E-D672831D716AQ34035243-B269416C-EF70-4026-9FBE-8CE2EE747B5AQ34774854-2F3BA3EB-9DDB-4D0C-9BAE-4ACB704CB161Q34871636-203A8972-203A-4687-BDF5-E6B6DAEB48E4Q34897883-F5E7938B-B102-4F2C-B2A5-C06659F511B1Q36110576-BBD0E9E7-69F2-460E-A9D4-C1AE2917177EQ37143617-0FD0577C-C5EB-41BB-8E5F-FBB0140E51E3Q37164563-3CBCA36C-506F-4DC3-84A0-AAB3A08FEC1DQ37235629-8261CB47-EC43-4C51-B8E8-7FD7042FDA0FQ37371551-ABF30CD8-3464-4DDC-828A-DFC02268E39EQ37481450-01B8DA3B-6DE4-40B1-B3B5-930F05AEDE39Q37533506-5B42A963-727F-4B75-B33D-F98ADABE814FQ37740126-7CFB8E9B-4C4D-4A90-97FB-FD372A80C3C5Q37793056-3A2A270B-92E4-4431-8411-E6F2D18160FEQ37958162-D7E6B648-8C7F-4D47-BDB0-216FC078B506Q38003174-31D5F76D-4CA8-40C4-9E79-B07E26025806Q38071700-F39DF572-3718-4AA7-85FA-D472351FB165Q38207943-402C4361-620A-4414-89C3-3BFFF97BEB98Q38379295-216452C5-BDFF-47FE-87E0-BE9ACFF5902DQ38691481-7E79C81A-7AEA-42CB-8F89-E94FF64F580DQ39140289-A3232FC9-F785-4C50-9726-8F9FEF2B98C1Q39486373-C1F13F27-7015-45CB-A424-D2D5CC8DEB39Q40956563-589A00E1-3216-4701-A75B-9E6648B0B983Q40971398-95AEA50B-01E7-4B0A-B569-0D7ECED0B292Q41595459-BF725467-C9A6-4797-AF57-78E4FA2D1409Q42637698-FA469B7E-8973-4D87-B928-2A5337C4F726Q43190795-D41209E6-7EAA-40C8-878A-CF03462AFD68Q43258273-26D18F3A-54ED-4CCF-9942-7C6532B11EBFQ43272335-D7F7675A-CF1F-4AED-89FC-D61BE7917D81Q44737065-631018F7-E4BE-4354-97D1-1662ECDC6E54Q45960885-A1464276-564A-48DA-B718-03794233D3C7Q45993642-75C52484-CFFC-4668-8428-67CF8C7DD524Q46018199-01B70506-5C01-46DB-9A78-4F181229AF96Q46369173-DD55B7D5-ED86-439B-BAD3-2CE6333E3E68Q46567504-733749A3-7118-4317-9151-D08248832492Q48811919-E7C41D1A-493F-4AD0-A94C-3F2626EF7F33Q48893219-EED70931-D10A-49D4-B5EA-1762835F8529Q48899356-D8CF8B30-A881-46C2-8DE8-F65FFF9BA54F
P2860
Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2 (BCRP) gene polymorphisms in humans.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Pharmacogenetic characterizati ...... gene polymorphisms in humans.
@en
Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2
@nl
type
label
Pharmacogenetic characterizati ...... gene polymorphisms in humans.
@en
Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2
@nl
prefLabel
Pharmacogenetic characterizati ...... gene polymorphisms in humans.
@en
Pharmacogenetic characterization of sulfasalazine disposition based on NAT2 and ABCG2
@nl
P2093
P2860
P356
P1476
Pharmacogenetic characterizati ...... gene polymorphisms in humans.
@en
P2093
H Kusuhara
P2860
P304
P356
10.1038/SJ.CLPT.6100459
P407
P577
2008-01-02T00:00:00Z